Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Ongoing post-approval monitoring

5 evidence topics · 2 sources

Total T3 monitoring during maintenance treatment

“Once on a stable dose of EMCITATE, reassess total T3 levels once every 6 months and modify the dosage as clinically required.” (opens the prescribing information at this quote)

“An FDA-authorized LC-MS/MS test for the measurement of total T3 is not currently available. Currently available LC-MS/MS tests used to measure total T3 may vary in accuracy” (opens the prescribing information at this quote)

Vision assessment in children younger than 8 years

“For pediatric patients less than 8 years of age, consider periodic vision assessment during treatment with EMCITATE to rule out lens abnormalities (e.g., cataract formation)” (opens the prescribing information at this quote)

Serum T3 measurement: recommended analytical method

“In patients receiving TH analogues, particularly TRIAC, T3 levels should be measured using LC-MS whenever available.” (opens the source at this quote in a new tab)

“If LC-MS assays are unavailable, some specific immunoassays may show lower cross-reactivity between T3 and TRIAC.” (opens the source at this quote in a new tab)

Laboratory monitoring frequency

“Laboratory tests, including thyroid function diagnostics, should be performed at baseline and repeated at least annually, with frequency adapted to the clinical context and individual patient needs, including the emergence of new symptoms of hypothyroidism or thyrotoxicosis. In our clinical experience, this often corresponds to monitoring approximately twice per year.” (opens the source at this quote in a new tab)

“Liver function should be monitored more frequently in patients receiving medications with known hepatotoxic side effects.” (opens the source at this quote in a new tab)

Cardiac and bone monitoring

“Echocardiograms and ECGs should be performed at baseline and as clinically indicated.” (opens the source at this quote in a new tab)

“Bone mineral density assessment by dual-energy X-ray absorptiometry (DEXA) should be performed at baseline from puberty onward. Follow-up DEXA measurements should be guided by baseline findings and clinical context and may be repeated approximately every 3–5 years, where clinically indicated.” (opens the source at this quote in a new tab)